Anti–PD-1 Inhibitor–Related Pneumonitis in Non–Small Cell Lung Cancer
Open Access
- 31 March 2016
- journal article
- case report
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 4 (4), 289-293
- https://doi.org/10.1158/2326-6066.cir-15-0267
Abstract
The recent approval of two PD-1 inhibitors for the treatment of non–small cell lung cancer (NSCLC) has rapidly led to the widespread use of these agents in oncology practices. Pneumonitis has been recognized as a potentially life-threatening adverse event among NSCLC patients treated with PD-1 inhibitors; however, the detailed clinical and radiographic manifestations of this entity remain to be described. We report on two cases of anti–PD-1 pneumonitis in advanced NSCLC patients treated with nivolumab after its FDA approval. Both patients presented with ground-glass and reticular opacities and consolidations in a peripheral distribution on CT, demonstrating a radiographic pattern of cryptogenic organizing pneumonia. Consolidations were extensive and rapidly developed within 8 weeks of therapy in both cases. Both patients were treated with corticosteroids with subsequent improvement of respiratory symptoms and radiographic findings. One patient experienced recurrent pneumonitis after completing corticosteroid taper, or a “pneumonitis flare,” in the absence of nivolumab retreatment, with subsequent improvement upon corticosteroid readministration. With the increasing use of immune checkpoint inhibitors in a growing number of tumor types, awareness of the radiographic and clinical manifestations of PD-1 inhibitor–related pneumonitis will be critical for the prompt diagnosis and management of this potentially serious adverse event. Cancer Immunol Res; 4(4); 289–93. ©2016 AACR.Keywords
Funding Information
- NCI (1K23CA157631)
This publication has 16 references indexed in Scilit:
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2015
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatmentEuropean Journal of Radiology, 2015
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialThe Lancet Oncology, 2015
- Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survivalEuropean Journal of Radiology, 2015
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trialThe Lancet, 2014
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial PneumoniasAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Reversed Halo Sign on High-Resolution CT of Cryptogenic Organizing Pneumonia: Diagnostic ImplicationsAmerican Journal of Roentgenology, 2003